April 7, 2021 -- Shoreline Biosciences has raised $43 million in capital to accelerate the advancement of its induced pluripotent stem cell (iPSC) platform, focused on the development of next-generation natural killer (NK) cell and macrophage cell therapies.
The funds will also support the company's research efforts to create NK cell-specific chimeric antigen receptors (CARs), switchable CAR-NK cell engagers, and macrophage-specific CARs.
In addition, Shoreline has entered a strategic relationship with the Advanced Cell Therapy Laboratory of the University of California, San Diego to secure good manufacturing practice (GMP) manufacturing of the company's cell therapy products.
The financing was led by Boxer Capital.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
